Intuitive Surgical (NASDAQ:ISRG) saw its shares climb by more than 8% after reporting third-quarter earnings that exceeded analyst projections. The company’s strong results were fueled by the increasing adoption of its da Vinci surgical systems and a notable rise in procedure volumes. For the quarter, Intuitive Surgical posted adjusted earnings per share of $1.84, beating the Street estimate of $1.64. Revenue reached $2.04 billion, surpassing expectations of $2.01 billion and marking a 17% increase from the $1.74 billion reported during the same period last year. The company reported an 18% year-over-year increase in da Vinci procedures, while system placements rose to 379 units, up from 312 in Q3 2023. Among these, 110 were the new da Vinci 5 systems, reflecting the growing demand for advanced surgical technology. Intuitive's installed base of da Vinci systems expanded to 9,539 units, a 15% year-over-year growth. Revenue from instruments and accessories, a key indicator of surgical activity, surged 18% to $1.26 billion. Systems revenue also saw an increase, reaching $445 million compared to $379 million in the prior-year quarter.
I ntuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.